Over the past day, 18 140 new cases of coronavirus were detected in Russia.
A day earlier, the diagnosis was confirmed in 18,283 people in the country.
In total, since the beginning of the epidemic, 1 618 116 cases have been recorded in the country, of which 1 215 414 people (75.11%) recovered, including 14 854 over the past day.
From complications that developed against the background of COVID-19 and concomitant diseases, 27 990 patients (1.73%) died, 334 people died per day.
Rospotrebnadzor reports that over the entire period, more than 60.4 million laboratory tests for coronavirus were carried out, including 575 thousand in the last day.
About 385 thousand people remain under medical supervision.
In Moscow, 4952 new cases of the disease were detected, a day earlier - 5268. In addition to the capital, more than 500 cases of COVID-19 were recorded per day in St. Petersburg (854) and the Moscow region (535).
© Maxim Blinov / RIA Novosti
In Moscow, it is not yet planned to introduce an access system in connection with the spread of the coronavirus, said the head of the Department of Information Technologies of the capital, Eduard Lysenko.
"Moscow does not yet plan to introduce a pass system and limit the walks of townspeople by analogy with how it is currently done in France and in other countries of the world," Lysenko quoted TASS as saying.
He added that the solutions implemented in different states have features that depend, inter alia, on the IT infrastructure formed in a particular city or country.
Alexander Gorelov, deputy director for scientific work of the Central Research Institute of Epidemiology of Rospotrebnadzor, expressed the opinion that a possible peak in the incidence of COVID-19 in Russia could occur in the first decade or mid-November.
He noted that the increase in the incidence of coronavirus in different regions was observed at different times, so the timing of the peak may also differ.
“Roughly it will be the first decade - mid-November.
It is difficult to make a more accurate forecast, since the development of the epidemic process is influenced by many factors - both climatic and social, ”TASS quotes Gorelova.
The representative of the Central Research Institute of Epidemiology of Rospotrebnadzor clarified that the number of daily detected cases of coronavirus at its peak may approach 20 thousand.
Vaccine trials in the elderly
In turn, Nikita Lomakin, head of clinical trials of the Russian Sputnik V coronavirus vaccine, said that the first group of elderly volunteers received the COVID-19 vaccine.
According to him, there were no side effects among the participants in the experiment.
“The first group of participants was screened last Thursday (October 22 -
), was hospitalized on Sunday, and on October 28 she received a dose of the vaccine,” Lomakin said in an interview with the Izvestia newspaper.
He noted that the first group of elderly volunteers included 28 people.
Persons with cancer, viral hepatitis or allergic reactions, patients receiving cancer drugs or immunosuppressive therapy, as well as elderly people who have suffered an acute heart attack or acute stroke within a year, were not allowed to participate in the study.
Lomakin said that during a study among young people in the first 24-49 hours after the first dose of the vaccine, a pre-influenza state and fever were observed among the side effects.
"None of the participants in the studies of the older age group from those who received the vaccine on October 28 had these reactions ... We did not notice any manifestations ... No skin reactions, no fever, no premorbid (preinfluenza) background", - Lomakin emphasized.
According to the head of the trials, this effect can be explained by the fact that the immune system of the elderly is slightly suppressed, and they do not respond so brightly to the vaccine.
Along with this, Lomakin explained that the participants in the trials are hospitalized twice - after receiving the first dose of the vaccine for six days and two weeks later for three days to administer the second dose of the vaccine.
“Within six months, these patients are checked: they will come to the hospital, they will be contacted by phone.
They will take different blood tests (a very large panel) in order to clarify some issues both from the point of view of safety and from the scientific side, ”added Lomakin.
A total of 110 people are planned to be included in the study on risk groups.
Let us remind you that the Sputnik V vaccine of the Gamaleya Center was registered in Russia in August, and the EpiVacCorona vaccine of the Vector Center was registered in October.
Another drug is at the stage of clinical trials, the development of which was led by the Chumakov Center for Research and Development of Immunobiological Drugs of the Russian Academy of Sciences.